ArticleFrontiers in oncology2025
Deep learning analysis of MRI to assess rectal cancer treatment.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04380337 (Phase II Trial of Organ Preservation Program Using Short-Course Radiation and FOLFOXIRI for Rectal Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Organ Preservation Program Using Short-Course Radiation and FOLFOXIRI for Rectal Cancer (SHORT-FOX)
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Traditional neoadjuvant therapy for locally advanced rectal cancer (LARC) results in pathologic complete response (pCR) in approximately 15% of patients, supporting non-operative strategies for those with clinical complete response (cCR). The subjectivity and variability in MRI-based cCR assessments highlight the need for objective, quantitative tools. Objective: To develop deep learning models for automated rectal tumor segmentation on pre- and post-treatment MRIs, and to identify radiomic features differentiating cCR from non-cCR patients. Materials and methods: We retrospectively analyzed pre- and post-treatment MRIs from 37 LARC patients enrolled in a Phase 2 TNT trial (NCT04380337). Rectal tumors were segmented on T2-weighted images by two data scientists, refined by a radiologist (reference standard), and independently segmented by a fellow. For pre-treatment segmentation, Model 1 (baseline; Results: For pre-treatment segmentation, radiologist-fellow inter-rater agreement was DSC Conclusion: This study demonstrates the feasibility of deep learning-based automated segmentation and radiomic profiling for differentiating treatment response in rectal cancer. Semi-supervised learning with pseudo-labeled data significantly improved segmentation performance, offering a practical approach to overcome limited annotations. Radiomic features warrant validation in larger multi-center studies for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.